IP Library Patent Application 14256947
Patent Application
App. No. 14/256,947

Purified Cell Population Isolated from Whole Blood

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/256,947
Abstract

A purified solution of human plasma, MNCs and platelets isolated from whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue wherein said purified solution comprises at least 90% by number of the MNCs in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue, said purified solution comprises at most 10% by number of the red blood cells and granulocytes in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue, and said purified solution is isolated and separated from said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue during a single centrifugation run.

Claims (23)

1 . A purified solution of human plasma, MNCs and platelets isolated from whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue wherein:

a. said purified solution comprises at least 90% by number of the MNCs in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue;

b. said purified solution comprises at most 10% by number of the red blood cells and granulocytes in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue; and

c. said purified solution is isolated and separated from said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue during a single centrifugation run.

2 . The purified solution of claim 1 wherein said purified solution comprises at least 95% by number of the MNCs in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue.

3 . The purified solution of claim 1 wherein said purified solution comprises at most 5% by number of the red blood cells in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue.

4 . The purified solution of claim 2 wherein said purified solution comprises at most 5% by number of the red blood cells in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue.

5 . The purified solution of claim 1 wherein said purified solution is isolated using a single disposable cartridge.

6 . The purified solution of claim 1 wherein said purified solution comprises at most 10% by number of the granulocytes in said whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue.

7 . A purified solution of MNCs comprising at least 90% MNCs by weight wherein:

a. said solution is purified from a sample of whole blood, bone marrow, or stromal vascular fraction cells separated from adipose tissue;

b. said solution is purified by depleting at least 90% of RBCs from said sample without the use of a density gradient medium or buffer; and

c. said solution is purified within a single disposable unit.

8 . The purified solution of claim 7 comprising at least 95% MNCs by weight.

9 . The purified solution of claim 7 wherein at least 95% of said RBCs are depleted from said sample.

10 . A purified solution of human plasma, MNCs and platelets created by:

a. depleting at least 90% of the RBCs from a sample of whole blood, bone marrow, or vascular stromal fraction cells separated from adipose tissue;

b. wherein said depletion occurs in an accelerated frame of reference, within a single disposable device, and without the use of a density gradient medium or a buffer.

11 . The purified solution of human plasma, MNCs and platelets of claim 10 created by depleting at least 95% of the RBCs from a sample of whole blood, bone marrow, or vascular stromal fraction cells derived from adipose tissue.

12 . A purified solution of human plasma, MNCs and platelets created by:

a. depleting at least 90% of the RBCs from a sample of whole blood, bone marrow, or vascular stromal fraction cells separated from adipose tissue;

b. wherein said depletion occurs under more than one gravity of acceleration, within a single disposable device, and without the use of a density gradient medium or a buffer.

13 . The purified solution of human plasma, MNCs and platelets of claim 12 created by depleting at least 95% of the RBCs from a sample of whole blood, bone marrow, or vascular stromal fraction cells separated from adipose tissue.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: SYNGEN INC.
To: THERMOGENESIS CORP.
Reel/Frame 043448/0601 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 20, 2016
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS RETIRING AGENT
To: SOLAR CAPITAL LTD., AS SUCCESSOR AGENT
Reel/Frame 039080/0063 →
ASSIGNMENT OF SECURITY INTEREST Recorded May 19, 2016
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC
Reel/Frame 038754/0977 →
SECURITY INTEREST Recorded Jul 16, 2015
From: SYNGEN INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 036109/0977 →